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BACKGROUND: Women with adnexal mass suspected of ovarian measures, and stratified by menopausal status, stage, and histologic
malignancy are likely to benefit from consultation with a gynecologic
oncologist, but imaging and biomarker tools to ensure this referral show
low sensitivity and may miss cancer at critical stages.
OBJECTIVE: The multivariate index assay (MIA) was designed to
improve the detection of ovarian cancer among women undergoing sur-
gery for a pelvic mass. To improve the prediction of benign masses, we
undertook the redesign and validation of a second-generation MIA
(MIA2G).
STUDY DESIGN:MIA2G was developed using banked serum samples
from a previously published prospective, multisite registry of patients who
underwent surgery to remove an adnexal mass. Clinical validity was then
established using banked serum samples from the OVA500 trial, a second
prospective cohort of adnexal surgery patients. Based on the final pa-
thology results of the OVA500 trial, this intended-use population for MIA2G
testing was high risk, with an observed cancer prevalence of 18.7% (92/
493). Coded samples were assayed for MIA2G biomarkers by an external
clinical laboratory. Then MIA2G results were calculated and submitted to a
clinical statistics contract organization for decoding and comparison to MIA
results for each subject. Sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) were calculated, among otherCite this article as: Coleman RL, Herzog TJ, Chan DW,
et al. Validation of a second-generation multivariate index
assay for malignancy risk of adnexal masses. Am J Obstet
Gynecol 2016;215:82.e1-11.
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RESULTS: Three MIA markers (cancer antigen 125, transferrin, and
apolipoprotein A-1) and 2 new biomarkers (follicle-stimulating hormone
and human epididymis protein 4) were included in MIA2G. A single cut-off
separated high and low risk of malignancy regardless of patient meno-
pausal status, eliminating potential for confusion or error. MIA2G speci-
ficity (69%, 277/401 [n/N]; 95% confidence interval [CI], 64.4e73.4%)
and PPV (40%, 84/208; 95% CI, 33.9e47.2%) were significantly
improved over MIA (specificity, 54%, 215/401; 95% CI, 48.7e58.4%,
and PPV, 31%, 85/271; 95% CI, 26.1e37.1%, respectively) in this
cohort. Sensitivity and NPV were not significantly different between the 2
tests. When combined with physician assessment, MIA2G correctly
identified 75% of the malignancies missed by physician assessment alone.
CONCLUSION:MIA2G specificity and PPV were significantly improved
compared with MIA, while sensitivity and NPV were unchanged. The
second-generation test significantly improved the predicted efficiency of
triage vs MIA without sacrificing high sensitivity and NPV, which are
essential for effectiveness.
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The number of women diagnosed
annually with adnexal mass far exceeds
the number of ovarian cancer cases,
posing a serious clinical challenge to
accurately identify the subgroup of pa-
tients most likely to beneﬁt from
consultation with a gynecologic oncolo-
gist. Although numerous prediction
models and referral guidelines have been
tested in the preoperative evaluation of
the adnexal mass, no single method has
received widespread acceptance.1-3 In
addition, numerous studies indicate thatthe majority of new ovarian cancer cases
fail to be appropriately referred or treated
at the time of ﬁrst surgery, with signiﬁ-
cant detrimental effects on 5-year
survival.4-6
To improve the presurgical detection of
ovarian cancer among women undergo-
ing removal of adnexal masses, the
multivariate index assay (MIA)OVA1was
developed. The test was cleared by the
Food and Drug Administration (FDA) in
2009 for presurgical risk assessment
limited to cases where adnexal excision is
warranted, and validated in 2 previously
published clinical trials.7,8 The MIA
combined the results of the biomarker
concentrations from the Siemens BNII
assays (Siemens, Malvern, PA) for apoli-
poprotein A-1, transthyretin, beta-2-
microglobulin, and transferrin (TRF)
and the Elecsys assay for cancer antigen
125 (CA125-II) (Roche, Indianapolis,
IN). In an intended-use clinical cohort
(adnexal surgery patients enrolled from
nongynecologic oncology practices),MIAshowed signiﬁcantly higher sensitivity for
predicting malignancy compared with
clinical impression, CA125-II, or modi-
ﬁed American Congress of Obstetricians
and Gynecologists (ACOG) criteria of
Dearking et al,9 and negative predictive
value (NPV) ranging from 95-98%.
Limitations of the MIA assay, however,
included a less than ideal speciﬁcity of
43-50%, as a consequence of a high false-
positive rate resulting in a positive
predictive value (PPV) of 30-42% in the
cohorts examined.7,10 These results pre-
dict that many patients with benign
masses may be classiﬁed as high risk,
reducing overall triage effectiveness.
The current study was undertaken to
evaluate the clinical validity of a second-
generation MIA (MIA2G), in which the
MIA panel was redesigned to improve
speciﬁcity and PPV of the assay while
maintaining high sensitivity and NPV.
Herein we report that the MIA2G
assay improves both speciﬁcity and PPV
relative to MIA without compromising
ajog.org GYNECOLOGY Original Researchsensitivity, NPV, or detection of early-
stage ovarian cancer.
Materials and Methods
The MIA2G algorithm was derived from
samples from an intended use cohort
described by Ueland et al.7 This pro-
prietary algorithm was derived from the
serum proteins apolipoprotein A-1,
CA125-II, human epididymis protein 4
(HE4), follicle-stimulating hormone
(FSH), and TRF using methods
described by the coauthors.11-13
For the validation study, archived
serum samples from an independent
prospectively collected set of specimense
theOVA500 studyewere used.8This study
cohort had the same enrollment criteria as
the OVA1 pivotal study7 and had been
previously evaluated for the ﬁrst-
generation serum biomarker MIA as part
of an independent veriﬁcation of MIA.
Consecutive patients who met inclusion
criteria were prospectively enrolled from
27 sites throughout theUnited States, all of
which had institutional review board
approval. All enrolling clinicians were
from nongynecologic oncology specialty
practices, although patients may have had
consultation with or undergone surgery
by a gynecologic oncologist. Inclusion
criteria were: women age 18 years,
signed informed consent, agreeable to
phlebotomy, and documented pelvicmass
planned for surgical intervention within
3 months of imaging. A pelvic mass was
conﬁrmed by imaging (computed to-
mography, ultrasonography, or magnetic
resonance imaging) prior to enrollment.
Exclusion criteria included a diagnosis of
malignancy in the previous 5 years (except
of nonmelanoma skin cancers) or enroll-
ment by a gynecologic oncologist. Meno-
pause was deﬁned as the absence of
menses for12months or age50 years.
Demographic and clinicopathologic in-
formation was collected on case report
forms.
A preoperative blood sample of 80
mL was processed within 1-6 hours of
collection, and serum was frozen at the
collection site. Serum samples were
shipped on dry ice to an archive site
(PrecisionMed Inc, Solana Beach, CA)
where they were thawed and aliquoted,
then frozen and stored at e65 toe85C. All aliquots were thawed only
once and consumed entirely during
testing, so that no sample had under-
gone >2 or <2 freeze-thaw cycles.
Serum biomarker concentrations were
determined on the Roche cobas 6000
clinical analyzer, utilizing the c501 and
e601 modules. The c501 module is a
medium throughput (up to 600 sam-
ples/h), photometric detection module
used for clinical chemistry applications,
homogenous immunoassays, and whole
blood measurement. The e601 module
is a medium throughput electro-
chemiluminescent detection module
used for heterogeneous immunoassays.
Biomarker assays were run according to
the manufacturer’s instructions. All
measurements were performed on
coded samples (blinded as to patient
demographics or pathology outcome)
at the Clinical Laboratory Improvement
Amendmentse/College of American
Pathologistsecertiﬁed laboratory of
the Division of Clinical Chemistry,
Department of Pathology, Johns Hop-
kins Medical Institution. The MIA2G
combines the results of the biomarker
concentrations from the cobas assays for
apolipoprotein A-1, CA125-II, HE4,
FSH, and TRF. Assays for apolipopro-
tein A-1 and TRF are immunoturbidi-
metric assays; CA125-II, HE4, and FSH
assays use electrochemiluminescent
detection. Package inserts for these as-
says indicate a maximum coefﬁcient of
variation of 1.1-2.8% for repeatability
and 2.5%-4.5% for intermediate preci-
sion for serum samples on these indi-
vidual biomarker assays.
The MIA2G risk score was calculated
using software (OvaCalc, Version 4.0.0,
Vermillion, Inc., Austin, TX) that uses
the 5 biomarker values and a proprietary
algorithm to return a dimensionless
numerical score from 0.0-10.0. While
MIA was optimized using different cut-
offs of 5.0 (premenopausal) and 4.4
(postmenopausal) to separate higher-
from lower-risk subjects, MIA2G uses a
single risk cut-off of 5.0 regardless of
menopausal status).
In the original OVA500 trial, clini-
cians were required to document the
results of physical examination, family
history, imaging, laboratory tests, andJULY 2016 Ameformal presurgical assessment of malig-
nancy. In cases where a formal assess-
ment was done by a clinician, other than
the enrolling physician, the referral his-
tory and the specialty of the clinician
who made the prediction were recorded,
as was the specialty of the surgeon who
ultimately operated on each patient. To
reﬂect routine clinical judgment and
referral behavior, physicians were not
asked to either follow any speciﬁc pre-
diction algorithm or justify their pre-
diction. The same prospectively
obtained physician assessment (PA)
prediction of malignancy was utilized in
the present trial, to compare routine
clinical assessment to MIA2G indepen-
dently and in combination with PA.
Postoperative pathology diagnosis was
recorded at each enrolling site and
independently reviewed.
The coded sample MIA2G scores and
biomarker values were submitted to an
independent clinical statistics contract
research organization, Applied Clinical
Intelligence (Bala Cynwyd, PA), where
they were matched by a subject identiﬁer
to the information from the case report
form and used for statistical analyses.
Clinical diagnostic performance criteria
(sensitivity, speciﬁcity, NPV, and PPV)
were calculated for MIA2G alone, PA
alone, and MIA2G þ PA.
Triage decision rules followed those
previously published for MIA.7,8 The
combined test result was declared posi-
tive when the patient had either a high-
risk MIA2G score or the presurgical PA
predicted a malignancy. Accordingly,
MIA2G þ PA was scored negative only
when both MIA2G and PA predicted a
benign outcome. A subset of the
OVA500 cohort meeting study inclu-
sion/exclusion criteria had MIA scores
generated as part of a previously pub-
lished study,8 and these data were used
for comparison (N ¼ 493).
Statistical analyses were performed
with software (SAS, Version 9.2 or later;
SAS Institute Inc, Cary, NC). Sensitivity
was deﬁned as: (test positives/all subjects
with identiﬁed malignancy)  100.
Speciﬁcity was deﬁned as: (test nega-
tives/all subjects without identiﬁed
malignancy)  100. PPV was deﬁned as:
(true test positives/all test positiverican Journal of Obstetrics& Gynecology 82.e2
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(true test negatives/all test negative
subjects)  100. Overall accuracy was
deﬁned as: (true test positivesþ true test
negatives)/all subjects)  100. TheseTABLE 1
Demographics and pathology of OVA50
All enrol
N ¼ 519
Age, y
N 519
Mean (SD) 48.4 (1
Median 47
Range (minimum, maximum) 18, 87
Ethnicity/race, n (%)
Asian 13 (2.5
Black or African American 86 (16.
Native Hawaiian/Pacific islander 1 (0.2
White 365 (70.
Other 5 (1.0
Hispanic or Latino 49 (9.4
Surgery performed, n (%)
Yes 511 (98.
No 8 (1.5
Time to surgery, wk
N 511
Mean (SD) 2.1 (2
Median 1
Range (minimum, maximum) 0, 24
Specialty of surgeon, n (%)
Obstetrics/gynecology 212 (40.
Gynecological oncology 299 (57.
Pathology diagnosis, n (%)
Benign ovarian tumor 415 (80.
Nonovarian primary malignancy
with no involvement of ovaries
4 (0.8
Nonovarian primary malignancy
with involvement of ovaries
6 (1.2
Low malignant potential
(borderline)
17 (3.3
Primary malignant ovarian
malignancy
69 (13.
Coleman et al. Validation of MIA2G for ovarian cancer. Am
82.e3 American Journal of Obstetrics& Gynecoloclinical performance measures are pre-
sented as a percentage score, followed by
the numbers of subjects that deﬁne the
measure, followed by the 95% conﬁ-
dence interval (CI) of the measure.0 clinical cohort
led subjects
Evaluable subjects
All evaluable subjects
N ¼ 493
Premeno
N ¼ 276
493 276
4.32) 48.6 (14.16) 39.5 (8.
48 41
18, 87 18, 60
) 13 (2.6) 8 (2.9)
6) 81 (16.4) 54 (19.6
) 1 (0.2) 1 (0.4)
3) 347 (70.4) 173 (62.7
) 5 (1.0) 4 (1.4)
) 46 (9.3) 36 (13.0
5) 493 (100.0) 276 (100
) 0 (0.0) 0 (0.0)
493 276
.19) 2.0 (1.72) 1.9 (1.
1 1
0, 11 0, 10
8) 204 (41.4) 144 (52.2
6) 289 (58.6) 132 (47.8
0) 401 (81.3) 245 (88.8
) 4 (0.8) 1 (0.4)
) 6 (1.2) 2 (0.7)
) 17 (3.4) 5 (1.8)
3) 65 (13.2) 23 (8.3)
J Obstet Gynecol 2016.
gy JULY 2016Wilson14 score-corrected 95% CI was
used throughout to provide better esti-
mates for smaller subgroups. McNemar
test was used to test the marginal ho-
mogeneity of the proportions of truepausal women Postmenopausal women
N ¼ 217
217
96) 60.2 (10.74)
60
33, 87
5 (2.3)
) 27 (12.4)
0 (0.0)
) 174 (80.2)
1 (0.5)
) 10 (4.6)
.0) 217 (100.0)
0 (0.0)
217
68) 2.1 (1.76)
2
0, 11
) 60 (27.6)
) 157 (72.4)
) 156 (71.9)
3 (1.4)
4 (1.8)
12 (5.5)
42 (19.4)
(continued)
TABLE 1
Demographics and pathology of OVA500 clinical cohort (continued)
All enrolled subjects
N ¼ 519
Evaluable subjects
All evaluable subjects
N ¼ 493
Premenopausal women
N ¼ 276
Postmenopausal women
N ¼ 217
If malignant ovarian malignancy:
predominant histology, n (%)
Epithelial: serous 24 (4.6) 24 (4.9) 8 (2.9) 16 (7.4)
Epithelial: mucinous 12 (2.3) 9 (1.8) 1 (0.4) 8 (3.7)
Epithelial: endometrioid 13 (2.5) 13 (2.6) 5 (1.8) 8 (3.7)
Epithelial: clear cell 5 (1.0) 5 (1.0) 1 (0.4) 4 (1.8)
Epithelial: carcinosarcoma 1 (0.2) 1 (0.2) 1 (0.4) 0 (0.0)
Epithelial: mixed 2 (0.4) 1 (0.2) 0 (0.0) 1 (0.5)
Other 12 (2.3) 12 (2.4) 7 (2.5) 5 (2.3)
Tumor grade, n (%)
N 69 65 23 42
1 9 (13.0) 9 (13.8) 1 (4.3) 8 (19.0)
2 12 (17.4) 10 (15.4) 4 (17.4) 6 (14.3)
3 43 (62.3) 41 (63.1) 15 (65.2) 26 (61.9)
Not graded 5 (7.2) 5 (7.7) 3 (13.0) 2 (4.8)
Tumor stage, n (%)
N 69 65 23 42
I 30 (43.5) 28 (43.1) 9 (39.1) 19 (45.2)
II 7 (10.1) 7 (10.8) 2 (8.7) 5 (11.9)
III 26 (37.7) 25 (38.5) 10 (43.5) 15 (35.7)
IV 6 (8.7) 5 (7.7) 2 (8.7) 3 (7.1)
Coleman et al. Validation of MIA2G for ovarian cancer. Am J Obstet Gynecol 2016.
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pairs of diagnostic tests under consid-
eration. Additionally, statistics included
CI for the differences between the risk
indices taking into account the corre-
lated nature of the indices,15 receiver
operator characteristic (ROC) curve,
ROC area under the curve (AUC), and
their corresponding CIs. The P value
from a test of the equality of the areas
under the empirical ROC curves is
presented (using methods indicated by
DeLong et al16 as implemented in SAS,
Version 9.4 software). Differences in
ratios were considered signiﬁcant if the
lower bound of the CI for a difference
comparison was>0 or the lower bound
for a ratio comparison was >1. A total
of approximately 500 evaluable subjects
in the validation subset with anassumed prevalence of 20% would
provide 95% 2-tailed CIs for estimates
of sensitivity (%) and speciﬁcity (%)
within 7% and 5% (absolute),
respectively, using the deﬁned cut-off
value and assuming comparable levels
of sensitivity and speciﬁcity seen in
previous studies. Under the same
assumption, the 95% 2-tailed CI would
be at4.0% for PPV(%) and2.0% for
NPV(%).
Results
This study followed a Prospective Spec-
imen Collection Retrospective Blinded
Evaluation design17 using clinically an-
notated sera collected for the OVA500
trial. From August 2010 through
December 2011 a total of 520 subjects
were consecutively enrolled, all of whomJULY 2016 Ameprovided a specimen. One subject was
found to have been enrolled twice,
leaving 519 for analysis. Subjects were
excluded from the ﬁnal analysis for:
failed exclusion criteria (imaging outside
of window prior to inclusion, surgery
>12 weeks, previous cancer <5 years,
n ¼ 12), primary contact was a gyneco-
logic oncologist (n ¼ 6), and no ovarian
pathology (n ¼ 8). The remaining 493
fully evaluable patients were scored after
MIA2G testing. The demographic char-
acteristics of the subject cohort are pre-
sented in Table 1. All 493 subjects had a
nongynecologic oncologist as their pri-
mary contact. The specialty of physicians
making the clinical assessment was a
nongynecologic oncologist in 249 pa-
tients and a gynecologic oncologist in
244 patients.rican Journal of Obstetrics& Gynecology 82.e4
TABLE 2
Clinical performance of second-generation multivariate index assay, presurgical physician assessment, and combination for all evaluable subjects and by
menopausal status
Evaluable subjects
N ¼ 493
Premenopausal women
N ¼ 276
Postmenopausal women
N ¼ 217
MIA2G PA MIA2G þ PA MIA2G PA MIA2G þ PA MIA2G PA MIA2G þ PA
Sensitivity % 91.3 73.9 93.5 90.3 74.2 90.3 91.8 73.8 95.1
n/N 84/92 68/92 86/92 28/31 23/31 28/31 56/61 45/61 58/61
95% CI 83.8e95.5 64.1e81.8 86.5e97.0 75.1e96.7 56.8e86.3 75.1e96.7 82.2e96.4 61.6e83.2 86.5e98.3
Specificity % 69.1 92.8 64.8 71.4 93.9 67.3 65.4 91.0 60.9
n/N 277/401 372/401 260/401 175/245 230/245 165/245 102/156 142/156 95/156
95% CI 64.4e73.4 89.8e94.9 60.0e69.4 65.5e76.7 90.1e96.3 61.2e72.9 57.6e72.4 85.5e94.6 53.1e68.2
Positive predictive value, % 40.4 70.1 37.9 28.6 60.5 25.9 50.9 76.3 48.7
n/N 84/208 68/97 86/227 28/98 23/38 28/108 56/110 45/59 58/119
95% CI 33.9e47.2 60.4e78.3 31.8e44.3 20.6e38.2 44.7e74.4 18.6e34.9 41.7e60.1 64.0e85.3 39.9e57.6
Negative predictive value, % 97.2 93.9 97.7 98.3 96.6 98.2 95.3 89.9 96.9
n/N 277/285 372/396 260/266 175/178 230/238 165/168 102/107 142/158 95/98
95% CI 94.6e98.6 91.1e95.9 95.2e99.0 95.2e99.4 93.5e98.3 94.9e99.4 89.5e98.0 84.2e93.7 91.4e99.0
Positive likelihood ratio 2.953 10.220 2.658 3.161 12.118 2.766 2.652 8.220 2.432
95% CI 2.518e3.463 7.053e14.811 2.303e3.069 2.514e3.975 7.115e20.639 2.234e3.425 2.111e3.332 4.879e13.850 1.983e2.982
Negative likelihood ratio 0.126 0.281 0.101 0.135 0.275 0.144 0.125 0.288 0.081
95% CI 0.065e0.245 0.199e0.397 0.046e0.219 0.046e0.398 0.151e0.500 0.049e0.423 0.054e0.293 0.189e0.440 0.027e0.245
Pretest odds of ovarian
malignancy
0.23:1 0.23:1 0.23:1 0.13:1 0.13:1 0.13:1 0.39:1 0.39:1 0.39:1
Posttest odds of ovarian
malignancy with high-risk score
0.68:1 2.34:1 0.61:1 0.40:1 1.53:1 0.35:1 1.04:1 3.21:1 0.95:1
Posttest odds of no ovarian
malignancy with low-risk score
34.63:1 15.50:1 43.33:1 58.33:1 28.75:1 55.00:1 20.40:1 8.88:1 31.67:1
Positive combined test result is when woman has high-risk index score or presurgical PA was malignant. When woman has both low-risk index score and benign presurgical PA, combined test result is negative.
CI, confidence interval; MIA2G, second-generation multivariate index assay; PA, physician assessment.
Coleman et al. Validation of MIA2G for ovarian cancer. Am J Obstet Gynecol 2016.
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FIGURE 1
Performance of MIA2G alone and with PA
Receiver operator characteristic (ROC) curves of MIA2G: A, for all evaluable women; B, for premenopausal women, and C, for postmenopausal women
comparing MIA2G alone (blue lines) and MIA2Gþ PA (red lines). ROC curves were obtained from logistic regression in prediction of malignancy. Mosaic
plot of clinical performance of: D to F, MIA2G alone; and G to I, in combination with PA. Mosaic plots are presented for: D and G, all evaluable women; E
and H, premenopausal women; and F and I, postmenopausal women. Mosaic plots show comparisons of relative numbers of patients in each category of
high or low MIA2G risk and whether patients with risk score were malignant or benign.
Sn, sensitivity; Sp, specificity.
Coleman et al. Validation of MIA2G for ovarian cancer. Am J Obstet Gynecol 2016.
ajog.org GYNECOLOGY Original ResearchThe diagnosis from pathology for all
subjects and for subjects stratiﬁed by
menopausal status is also presented in
Table 1. Overall, the prevalence of pelvic
malignancy among evaluable patients
was 19% (92/493). Of these, 65 (13%)
were invasive primary ovarian malig-
nancies and 17 (3%) were low malig-
nant potential (borderline) tumors.
Documented pelvic malignancies alsoincluded 6 malignancies metastatic to
the ovaries (1%) and 4 nonovarian
malignancies (1%). The overall preva-
lence in premenopausal subjects was
11% while the prevalence in post-
menopausal subjects was 28%. The
primary ovarian malignancies were
assigned subtype, stage, and grade in-
formation, where possible. Eleven
(48%) of the invasive ovarian cancers inJULY 2016 Amepremenopausal women were found to
be early stage (I/II) and 24 (57%) of the
invasive ovarian cancers in post-
menopausal women were early stage. In
all, 401 patients (81%) had benign
conditions.
The performance of MIA2G in pre-
dicting malignancy both alone and in
combination with PA is shown in
Table 2. In summary, MIA2G alonerican Journal of Obstetrics& Gynecology 82.e6
TABLE 3
Performance of second-generation multivariate index assay by histological subtype of malignancy and by stage of
primary ovarian malignancy for all evaluable subjects and stratified by menopausal status
Evaluable subjects
N ¼ 493
Premenopausal women
N ¼ 276
Postmenopausal women
N ¼ 217
% n/N 95% CI % n/N 95% CI % n/N 95% CI
Histological subtype
EOC 95.0 57/60 86.3e98.3 100.0 18/18 82.4e100.0 92.9 39/42 81.0e97.5
Non-EOC malignancies 80.0 4/5 37.6e96.4 80.0 4/5 37.6e96.4 e 0/0 e
Low malignant potential 82.4 14/17 59.0e93.8 80.0 4/5 37.6e96.4 83.3 10/12 55.2e95.3
Metastatic to ovaries 100.0 6/6 61.0e100.0 100.0 2/2 34.2e100.0 100.0 4/4 51.0e100.0
Other nonovarian malignancies 75.0 3/4 30.1e95.4 0 0/1 0.0e79.3 100.0 3/3 43.9e100.0
Stage of primary ovarian malignancy
I 85.7 24/28 68.5e94.3 88.9 8/9 56.5e98.0 84.2 16/19 62.4e94.5
II 100.0 7/7 64.4e100.0 100.0 2/2 34.2e100.0 100.0 5/5 56.6e100.0
All early stage (I or II) 88.6 31/35 74.0e95.5 90.9 10/11 62.3e98.4 87.5 21/24 69.0e95.7
III 100.0 25/25 86.7e100.0 100.0 10/10 72.2e100.0 100.0 15/15 79.6e100.0
IV 100.0 5/5 56.6e100.0 100.0 2/2 34.2e100.0 100.0 3/3 43.9e100
All late stage (III or IV) 100.0 30/30 88.6e100.0 100.0 12/12 75.8e100.0 100.0 18/18 82.4e100.0
CI, confidence interval; EOC, epithelial ovarian cancer.
Coleman et al. Validation of MIA2G for ovarian cancer. Am J Obstet Gynecol 2016.
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nation of MIA2G þ PA showed a sensi-
tivity of 94%. Adding MIA2G to PA
correctly identiﬁed 75% of the malig-
nancies missed by PA alone (P < .001
from McNemar test). The NPV of
MIA2Gþ PAwas 98%. PA alone showed
the best performance in correctly iden-
tifying benign disease.
Figure 1 presents ROC curves for all
evaluable patients and patients stratiﬁed
by menopausal status for MIA2G alone
or combined with PA. The ROC curves
were derived from logistic regression of
clinical data. The mosaic plots (Figure 1,
D-I) depict the confusion matrix of high-
and low-risk test results vs malignant and
benign patients. These plots show the
performance of the test at the ﬁxed cut-
off of 5.0 for all evaluable women and
both premenopausal and post-
menopausal women. PA and MIA2G
agreed on 72% of all cases. When PAwas
combined with MIA2G, sensitivity was
increased by 2% overall, with a 4%
reduction in speciﬁcity compared to
MIA2G alone. Addition of PA had no
effect on premenopausal sensitivity of82.e7 American Journal of Obstetrics& GynecoloMIA2G (90%), but increased sensitivity
from 92-95% in postmenopausal sub-
jects. The speciﬁcity of MIA2G was
slightly higher in premenopausal vs
postmenopausal patients (71% vs 65%,
respectively), and this difference was
maintained with the addition of PA (67%
vs 61%, respectively) (Table 2).
The performance of MIA2G for his-
tological subtype of ovarian cancer and
for International Federation of Gyne-
cology and Obstetrics stage (pre-January
1, 2014) of ovarian cancer, for all patients
and stratiﬁed by menopausal subgroup,
is summarized in Table 3. In summary,
MIA2G showed 95% sensitivity for
epithelial ovarian cancer; sensitivity was
100% for premenopausal women and
93% for postmenopausal women.
MIA2G also demonstrated a sensitivity
of 80% for nonepithelial ovarian cancer
primary malignancies and 82% for low
malignant potential tumors. MIA2G
demonstrated 86% sensitivity for stage I
ovarian cancers and 100% sensitivity for
stage II ovarian cancers.
Table 4 shows results comparing
clinical performance ofMIA2G andMIAgy JULY 2016for all evaluable subjects in this set of
serum samples, as well as CA125-II levels
that are consistent with clinical cut-off
values in accordance with published
ACOG referral criteria (200 U/mL for
premenopausal women or >35 U/mL
for postmenopausal women).3 The effect
of substituting the modiﬁed ACOG
criteria for premenopausal women 67
U/mL was also evaluated.9 In summary,
MIA2G demonstrated nearly identical
sensitivity to MIA and detected only 1
less malignancy overall. In contrast,
MIA2G demonstrated signiﬁcantly
higher speciﬁcity compared to MIA and,
because of improved test performance
among women with benign conditions,
the PPV of MIA2G was signiﬁcantly
higher than that of MIA, while the NPV
remained the same. Comparison of the 2
assays is also presented in Figure 2,
showing ROC curves for all evaluable
women and for premenopausal and
postmenopausal subgroups. Notably,
MIA2G showed statistically better ROC
AUC for all evaluable women (AUC of
MIA2G, 0.924; 95% CI, 0.892e0.956;
AUC of MIA, 0.862; 95% CI,
T
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JULY 2016 Ame0.814e0.911; P < .001) and for post-
menopausal women (AUC of MIA2G,
0.919; 95% CI, 0.878e0.960; AUC of
MIA, 0.855; 95% CI, 0.789e0.921; P <
.01). There was no statistical difference
in ROC AUC in premenopausal women
(AUC of MIA2G, 0.921; 95% CI,
0.860e0.981; AUC of MIA, 0.899; 95%
CI, 0.830e0.967; P > .1).
Overall accuracy [(true positives þ
true negatives)/all subjects]  100 was
increased by 12% for MIA2G (95% CI,
7.6e17.1) and 11% for MIA2G þ PA
(95% CI, 6.4e15.5%), when compared
to MIA and MIAþ PA. This represented
61 subjects whose classiﬁcation changed
from inaccurate to accurate when
MIA2G was substituted for MIAwithout
PA and 54 whose classiﬁcation changed
from inaccurate to accurate when
MIA2G was substituted for MIA
including PA. The difference in accuracy
between premenopausal and post-
menopausal subjects decreased from
10% for MIA to <1% for MIA2G. Ac-
curacy of MIA2G was 73% (95% CI,
66.5e78.3%) for postmenopausal sub-
jects and 74% (95%CI, 68.0e78.4%) for
premenopausal subjects.
CA125-II alone showed a sensitivity of
76% (70/92; 95% CI, 66.4e83.6%) for
all evaluable women, which stratiﬁed to
68% for premenopausal women (200 U/
mL cut-off) and 80% in postmenopausal
women (35 U/mL cut-off). The speci-
ﬁcity was 96% for premenopausal
women and 92% for postmenopausal
women. MIA2G detected 7 more early-
stage primary ovarian cancers than
CA125-II.
Comment
To improve triage of adnexal mass
scheduled for surgery, MIA2G design
focused on these critical attributes: (1)
high-sensitivity detection so as not to
miss any cancers that should be referred
to a specialist with a resulting high NPV
for ruling out cancer given a low-risk
result; (2) signiﬁcantly increased speci-
ﬁcity to provide fewer misclassiﬁcations
of benign ovarian conditions, resulting
in and increased PPV; and (3) harmo-
nized performance at a single cut-off to
eliminate the uncertainty in assessing
risk across menopausal strata, and torican Journal of Obstetrics& Gynecology 82.e8
FIGURE 2
ROC curves comparing MIA2G to MIA
Receiver operator characteristic curves comparing second-generation multivariate index assay (MIA) (blue lines) to MIA (red lines) for A, all evaluable
patients and stratified by B, premenopausal and C, postmenopausal women.
AUC, area under curve.
Coleman et al. Validation of MIA2G for ovarian cancer. Am J Obstet Gynecol 2016.
Original Research GYNECOLOGY ajog.orgeliminate the need to report menopausal
status in patient testing. The samples
used to validate MIA2G were prospec-
tively collected from female patients
scheduled to undergo surgery for an
adnexal mass. Based on the ﬁnal pa-
thology results of the OVA500 trial, this
study population was high risk and
presented with an increased cancer
prevalence. The results reported here
show that MIA2G achieved these design
goals by demonstrating equal or
improved clinical performance when
compared to MIA across a number of
attributes (with or without PA, stratiﬁed
by ovarian cancer stage, histological
subtype, and premenopausal vs post-
menopausal status.
A high-risk MIA2G result, with a 40%
PPV, correlated with a 2 in 5 chance of
malignancy; while a low-risk result
indicated a 98% chance of the mass be-
ing benign. Driving more malignant
masses to the gynecologic oncologist and
keeping more benign masses with the
gynecologist should help improve the
outcomes of women with ovarian cancer
while saving health care dollars, as well as
patient inconvenience and anxiety for
those with benign masses.
MIA2G showed >90% sensitivity
both independently and in combination
with PA. Of note is the ﬁnding that82.e9 American Journal of Obstetrics& GynecoloMIA2G demonstrated sensitivity that
was equivalent to or higher than other
diagnostic tools used in triage of adnexal
mass, including PA alone and CA125-II
with various cut-offs. No signiﬁcant
change in NPV was found with MIA2G
vs MIA, CA125-II, or PA alone. Overall,
1 fewer malignancy was classiﬁed as high
risk by MIA2G. The 8 malignant masses
classiﬁed as low risk by MIA2G (false-
negative test) included 1 metastatic
nonovarian, 3 low malignant potential
tumors, 3 stage I epithelial malignancy,
and 1 stage I nonepithelial malignancy.
Of these 8, 2 were classiﬁed as high risk
by PA (both stage 1 epithelial), while the
remaining 6 were classiﬁed as low risk by
PA. PA failed to predict 24 of 92 malig-
nancies, a false-negative rate of 26%. The
false-negative rate of MIA2G alone was
9%, while MIA2G þ PA showed a false-
negative rate of 7%ea 75% reduction
compared with PA.
Early-stage cancer is particularly
difﬁcult to predict using current diag-
nostic tools and guidelines.18 The overall
sensitivity of MIA2G for stage I primary
ovarian cancers was not statistically
different than for all ovarian cancer
stages (Table 3). For both premeno-
pausal and postmenopausal women the
sensitivity for stage I and all early-stage
cancer was similarly high, indicatinggy JULY 2016sensitivity was retained across meno-
pausal strata. The sensitivity for early-
stage cancer in all subjects was further
improved with the addition of PA
(MIA2Gþ PA to 93% for stage I [26/28;
95% CI, 77.4e98.0%] and 94% for all
early-stage cancers [33/35; 95% CI,
81.4e98.4%], data not shown). These
data indicated that MIA2G may be an
effective tool in managing early-stage
ovarian cancer, where intervention has
been shown to be most effective. Five-
year survival for stage I ovarian cancer
is 90% and for stage II is 70%, while for
stage III and IV is it 39% and 17%,
respectively.19
All of the serous cancers in this study
were high-grade malignancies and none
were missed by MIA2G þ PA, whereas 1
was missed by MIA þ PA, consistent
with retained sensitivity for this medi-
cally critical subtype. Overall, the results
suggest that MIA2G, like MIA, offers
high sensitivity with signiﬁcant PA
complementarity in the setting of
adnexal malignancy.
While high sensitivity and NPV is a
diagnostic priority for presurgical man-
agement of ovarian cancer, the modest
speciﬁcity and PPV of MIA potentially
pose barriers to adoption and effective
triage. Indeed, despite a favorable posi-
tion statement on MIA issued by the
ajog.org GYNECOLOGY Original ResearchSociety of Gynecologic Oncology,20
other guidelines such as the National
Comprehensive Cancer Network and
ACOG have not followed. In the present
study, speciﬁcity of MIA2G was
increased over MIA by 15% without PA
and 14% when combined with PA. As a
result, the total number of patients
identiﬁed as low risk with MIA2G alone
was increased from 45-58%, a 13% in-
crease. But in this cohort, the NPV was
97% for MIA2G and 97% for MIA. The
results suggest that MIA2G may sub-
stantially increase the percentage of pa-
tients whomay be treated locally by their
generalist providers, while maintaining
an equivalently low likelihood of malig-
nancy among patients classiﬁed as low
risk.
Strengths of the present study include
the comparison of MIA2G against MIA
results for each subject from a large,
prospectively collected and published,
multiinstitutional trial of MIA; as well as
the fact that MIA2G utilized industry-
leading platform and FDA-cleared
biomarker assays in the algorithm
design. These factors lend themselves to
robust analytical and clinical perfor-
mance compared with many biomarker
clinical trials. In addition, biomarker
testing and clinical statistics analysis
were independently performed, and all
ovarian tumor types were included in
the statistical analysis of test
performance.
A potential limitation of this study is
the lack of uniform preoperative evalu-
ation for comparison. This study was
designed to include only those patients
who received a PA independent of the
MIA score. This represented the most
realistic clinical surrogate given that
other referral algorithms are not uni-
formly followed in the United States.
Additionally, all women enrolled in this
trial were scheduled for surgery for an
adnexal mass, a population with
increased cancer prevalence compared
with those in whom surgery is not
planned. A population with lower cancer
prevalence would decrease the test’s PPV
and increase its NPV. A related limitation
is the lack of standardized imaging
criteria such as the International
Ovarian Tumor Analysis protocol, usedin some European nations.21 While
standardized, expert imaging may be
practical in some single-payer health
care systems abroad, the present study
evaluated incremental diagnostic per-
formance against actual PA, inclusive of
all assessment components. In addition a
separate manuscript has been submitted
for publication, using a simpliﬁed,
retrospective imaging risk score, which
was previously published for the MIA
test.22
The present ﬁndings have important
implications for ovarian cancer man-
agement at the very ﬁrst medical inter-
vention. Previous studies have shown
that most new ovarian cancer cases are
operated by low-volume physicians and
clinics that lack the preparation,
training, and knowledge to perform
surgical staging, radical cytoreduction,
and intraoperative chemotherapy.23-26
As a result, survival is statistically
signiﬁcantly compromised.25,27 Presur-
gical triage must carefully balance high
sensitivity, early-stage detection, and
high NPV against possible overreferral.
The present MIA2G validation study
demonstrates a signiﬁcant increase in
speciﬁcity and PPV over MIA, without
sacriﬁcing the sensitivity, NPV, PA
complementarity, or detection of early-
stage ovarian cancer. The clinical
outcome of these results can improve the
triage to the correct surgeon of adnexal
masses deemed necessary for surgical
removal by allowing gynecologists to
keep benign masses within their practice
and directing malignant masses to the
gynecologic oncologist. n
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